Context Therapeutics (CNTX) had its "buy" rating reaffirmed by D. Boral Capital. They now have a $9.00 price target on the stock.
Context Therapeutics (CNTX) had its "buy" rating reaffirmed by Guggenheim. They now have a $5.00 price target on the stock.
Context Therapeutics (CNTX) had its price target raised by Piper Sandler from $4.00 to $7.00. They now have an "overweight" rating on the stock.
Context Therapeutics Reports Full Year 2025 Operating and Financial Results [Yahoo! Finance]
Context Therapeutics GAAP EPS of -$0.38 [Seeking Alpha]